Breaking News, Collaborations & Alliances

Trenchant & Autolomous Partner to Accelerate Cell & Gene Therapy Manufacturing

Combine their platforms to address the timelines, costs, and challenges within the CGT manufacturing sector.

Author Image

By: Charlie Sternberg

Associate Editor

Trenchant BioSystems Inc., a CGT manufacturing platform developer for gene-modified cells, and Autolomous, a cloud-based, cell and gene therapy (CGT) software platform developer, are combining their platforms under the terms of a long-term partnership agreement that aims to address the timelines, costs and challenges within the CGT manufacturing sector.  As a result of the partnership, Trenchant BioSystems will integrate Autolomous’ autoloMATE digital solution into its automated CGT manufactu...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters